


Data Sheet

WWW.UREIKO-CHEM.COM

Global Supplier of Chemical Probes, Inhibitors & Agonists

Product Name	:Dovramilast (Synonyms: CC-11050)
Cat.No.	:URK-V2485
CAS No.	:340019-69-4
Molecular Formula	:C ₂₄ H ₂₈ N ₂ O ₆ S
Molecular Weight	:472.55
Target	:
Solubility	:



Biological Activity

Dovramilast is a selective phosphodiesterase 4 (PDE4) inhibitor that works by blocking the enzyme PDE4, which is responsible for the breakdown of cyclic adenosine monophosphate (cAMP) in inflammatory cells.

Dovramilast has shown a potent anti-inflammatory effect in reducing symptoms such as coughing, wheezing, and shortness of breath in patients with asthma.

The unique mechanism of action of Dovramilast makes it a promising drug for the treatment of airway diseases.

In addition, its oral administration and good safety profile make it an attractive option for long-term therapy.

References

1. Rennard SI, Calverley PM, Goehring UM, Bredenbroker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD. *Respir Res.* 2011;12:18.
2. Spina D. PDE4 inhibitors: current status and potential for the treatment of asthma. *Drugs.* 2008;68(5): 803-816.
3. Yamasaki K, Suzuki K, Ichinose M. Phosphodiesterase 4 inhibitors in the treatment of COPD and asthma: where are we now and where do we go from here? *Pharmacol Ther.* 2019;204:107398

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, we do not provide products and services for any personal use!

Caution: Product has not been fully validated for medical applications. Lab Use Only!

JACK@UREIKO-CHEM.COM